Sector Expert: Daniel Pearlstein

M Partners

Image: Daniel Pearlstein

Daniel Pearlstein is an equity research analyst with M Partners covering the Life Sciences sector. His previous experience includes analyst roles at a North American healthcare venture capital firm, a medical device startup and a technology transfer incubator. Pearlstein holds a bachelor's degree in chemistry and a master's degree in management.

Subscribe to
Streetwise Reports
Ask this Expert

Companies Commented On

  • Antibe Therapeutics Inc.
  • BriaCell Therapeutics Corp.
  • Cynapsus Therapeutics Inc.
  • TSO3 Inc.


Recent Interviews

Medical Marijuana Goes to Market: Daniel Pearlstein of M Partners (1/7/15)
Medical Marijuana

Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small- and micro-cap life sciences companies. In this interview with The Life Sciences Report, Pearlstein offers his perspectives on six Canadian biotech and specialty pharma names with different value propositions and the capacity to grow multiples of invested capital, including one company in the budding medical marijuana field.

Recent Quotes

"CYNA finished Q2/15 with over $111M in cash; it is well capitalized."

— Daniel Pearlstein, M Partners (8/19/15)
more >

"Early data on BCT's BriaVax is encouraging, which should drive the stock to appreciate."

— Daniel Pearlstein, M Partners (7/23/15)
more >

"CYNA closed its U.S. offering on June 23, raising $72.5M."

— Daniel Pearlstein, M Partners (7/7/15)
more >

"The definitive agreement sets up BCT to prepare enough samples for use in Phase 1/2 trials in Q4/15."

— Daniel Pearlstein, M Partners (6/17/15)
more >

"We continue to like CTH as a play in the Parkinson's space."

— Daniel Pearlstein, M Partners (5/27/15)
more >

"Yesterday, CTH announced a $21M private placement at $0.95."

— Daniel Pearlstein, M Partners (4/1/15)
more >

"CTH intends to submit a 505(b)(2) NDA to the FDA in mid-late 2016."

— Daniel Pearlstein, M Partners (3/12/15)
more >

"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous."

The Life Sciences Report Interview with Daniel Pearlstein (1/8/15)
more >

more comments

"CTH released positive top-line results from clinical trial CTH-105."

— Daniel Pearlstein, M Partners (11/20/14)
more >

"Fourteen of 16 Parkinson's disease patients treated with CTH's APL-130277 were converted from 'off' to 'on'."

— Daniel Pearlstein, M Partners (11/19/14)
more >

"For CTH, the Acorda/Civitas acquisition implies a $315M takeout."

— Daniel Pearlstein, M Partners (9/26/14)
more >

"CTH is set to begin Phase 2 clinical studies for APL-130277."

— Daniel Pearlstein, M Partners (7/21/14)
more >

fewer comments


Due to permission requirements, not all quotes are shown.